Jubilant and Cyclopharm terminate licensing agreement for Technegas
Both companies to discuss potential commercial opportunities once Cyclopharm obtains US FDA approval for Technegas
Jubilant DraxImage Inc (JDI), a wholly-owned subsidiary of Jubilant Life Sciences Ltd, and Cyclopharm Ltd have mutually terminated their previously announced term sheet for exclusive commercial rights of Technegas in the US market. Both parties have agreed to discuss potential commercial opportunities once Cyclopharm obtains US FDA approval for Technegas.
Technegas is used in ventilation lung imaging for pulmonary embolism. The Technegas technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,500°C. The resultant gaseous substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for the superior diagnosis of pulmonary emboli (blood clots in the lungs).
Technegas is used in ventilation lung imaging for pulmonary embolism. The Technegas technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,500°C. The resultant gaseous substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for the superior diagnosis of pulmonary emboli (blood clots in the lungs).